| scholarly article | Q13442814 |
| P2093 | author name string | Jann N Sarkaria | |
| Forest M White | |||
| Mark A Schroeder | |||
| Amanda M Del Rosario | |||
| Hannah Johnson | |||
| Bryan D Bryson | |||
| P2860 | cites work | The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor | Q24307577 |
| Identification of amino acids in the N-terminal SH2 domain of phospholipase C gamma 1 important in the interaction with epidermal growth factor receptor | Q24310814 | ||
| The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. | Q24534479 | ||
| Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl | Q24621898 | ||
| Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway | Q24650927 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Hrs interacts with sorting nexin 1 and regulates degradation of epidermal growth factor receptor | Q28139720 | ||
| Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7 | Q28146026 | ||
| Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules | Q28256069 | ||
| Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas | Q70463968 | ||
| Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors | Q71805186 | ||
| Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays | Q80237000 | ||
| Tyrosine residues in bovine phospholipase C-gamma phosphorylated by the epidermal growth factor receptor in vitro | Q28256314 | ||
| The phosphatase activity of carbonic anhydrase III is reversibly regulated by glutathiolation | Q28580690 | ||
| Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies | Q29615606 | ||
| Malignant astrocytic glioma: genetics, biology, and paths to treatment | Q29618156 | ||
| Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization | Q30164745 | ||
| Clustering by passing messages between data points | Q31091773 | ||
| Identification of differentially expressed proteins in human glioblastoma cell lines and tumors | Q31136179 | ||
| PTMScout, a Web resource for analysis of high throughput post-translational proteomics studies | Q34320730 | ||
| Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR. | Q34629812 | ||
| Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma | Q34655394 | ||
| Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery | Q35086666 | ||
| Vimentin in cancer and its potential as a molecular target for cancer therapy | Q35182104 | ||
| Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma | Q35627691 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks | Q35749545 | ||
| Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth | Q35793511 | ||
| EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins | Q36508737 | ||
| Eps15 mediates vesicle trafficking from the trans-Golgi network via an interaction with the clathrin adaptor AP-1. | Q36796883 | ||
| The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. | Q37300370 | ||
| The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling | Q38349130 | ||
| The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells | Q39409582 | ||
| SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration. | Q39703419 | ||
| Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway | Q39987247 | ||
| EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes | Q40156909 | ||
| Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. | Q40232913 | ||
| Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway | Q40410769 | ||
| Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme | Q40512036 | ||
| Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR | Q40619097 | ||
| Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer | Q40751670 | ||
| Identification of TrkB autophosphorylation sites and evidence that phospholipase C-gamma 1 is a substrate of the TrkB receptor | Q41486682 | ||
| Specific tyrosine phosphorylations mediate signal-dependent stimulation of SHIP2 inositol phosphatase activity, while the SH2 domain confers an inhibitory effect to maintain the basal activity | Q42455252 | ||
| YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene | Q42475185 | ||
| The role of S100 genes in breast cancer progression | Q42481244 | ||
| Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor | Q42799161 | ||
| Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression | Q42803600 | ||
| Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. | Q42812982 | ||
| Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. | Q43200792 | ||
| Requirement of autophosphorylated tyrosine 992 of EGF receptor and its docking protein phospholipase C gamma 1 for membrane ruffle formation | Q44314949 | ||
| Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. | Q45943467 | ||
| Intratumoral patterns of genomic imbalance in glioblastomas. | Q48230300 | ||
| The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. | Q50993792 | ||
| Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. | Q55472981 | ||
| Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas | Q55480632 | ||
| P433 | issue | 12 | |
| P921 | main subject | glioblastoma | Q282142 |
| xenograft | Q64148587 | ||
| tumour xenograft | Q112042499 | ||
| P304 | page(s) | 1724-1740 | |
| P577 | publication date | 2012-09-10 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts | |
| P478 | volume | 11 |
| Q37077653 | A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes. |
| Q24307468 | ATRX directs binding of PRC2 to Xist RNA and Polycomb targets |
| Q38238602 | Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. |
| Q38238607 | Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies. |
| Q37362563 | Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes. |
| Q26852366 | Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies |
| Q90543304 | Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification |
| Q35534349 | Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status |
| Q30600225 | Computer aided manual validation of mass spectrometry-based proteomic data |
| Q37289437 | Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics |
| Q38202550 | Discoidin domain receptors: a proteomic portrait |
| Q58605925 | EGFR cooperates with EGFRvIII to recruit macrophages in glioblastoma |
| Q36780907 | EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis |
| Q41495698 | Engineered bromodomains to explore the acetylproteome |
| Q38098098 | Epidermal growth factor receptor as a therapeutic target in glioblastoma |
| Q39680751 | Evaluation of phosphopeptide enrichment strategies for quantitative TMT analysis of complex network dynamics in cancer-associated cell signalling |
| Q47853903 | Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma. |
| Q38208372 | Extracellular RNA mediates and marks cancer progression |
| Q36713853 | Glioblastomas with copy number gains in EGFR and RNF139 show increased expressions of carbonic anhydrase genes transformed by ENO1. |
| Q30277399 | Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro |
| Q30588679 | Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling |
| Q34940926 | MARQUIS: a multiplex method for absolute quantification of peptides and posttranslational modifications |
| Q37420167 | Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis |
| Q35149540 | MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathways |
| Q37049816 | Network Modeling Identifies Patient-specific Pathways in Glioblastoma. |
| Q36225560 | Neutral Loss Is a Very Common Occurrence in Phosphotyrosine-Containing Peptides Labeled with Isobaric Tags |
| Q93054519 | Oncogenic Role of Guanylate Binding Protein 1 in Human Prostate Cancer |
| Q50053407 | Overexpression of centrosomal protein 55 regulates the proliferation of glioma cell and mediates proliferation promoted by EGFRvIII in glioblastoma U251 cells |
| Q33648713 | Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6 |
| Q36224594 | PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena |
| Q38257674 | Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. |
| Q35251771 | Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity |
| Q50077966 | Proteasome dysregulation in human cancer: implications for clinical therapies |
| Q38257671 | Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration |
| Q47854601 | Quantitative Analysis of Tyrosine Kinase Signaling Across Differentially Embedded Human Glioblastoma Tumors |
| Q35632892 | Quantitative Profiling of Lysine Acetylation Reveals Dynamic Crosstalk between Receptor Tyrosine Kinases and Lysine Acetylation |
| Q42998414 | Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma |
| Q38398440 | ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. |
| Q92784359 | Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring |
| Q37712428 | Reversible phosphorylation of the 26S proteasome. |
| Q47828321 | TRIM59 promotes gliomagenesis by inhibiting TC45 dephosphorylation of STAT3. |
| Q97542845 | The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma |
| Q36356011 | The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. |
| Q35388346 | Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. |
| Q37580494 | hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance |
Search more.